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Anisoylated plasminogen streptokinase activator com-
plex (APSAC) is a new thrombolytic agent that is of
Interest because of its ease of administration as an in-
travenous bolus injection. This report describes the first
double-blind, placebo-controlled evaluation of intrave-
nous APSAC tor coronary recanalization in acute myo-
cardial infarction. Unequivocal documentation of reca-
nalizationwas provided by coronary arteriography before
and after the drug intervention. Forty patients with acute
myocardial infarction underwent coronary arteriog-
raphy 3.1 ± 1.2 hours after the onset of symptoms. This
demonstrated occlusion of the infarct-related coronary
artery in 29 patients who were then randomized to treat-
ment with intravenous APSAC, 30 mg (n = 16), and
placebo (n = 13) 3.3 ± 1.3 hours after the onset of
symptoms.
Repeat arteriography 90 minutes later demonstrated
recanalization of the infarct-related coronary artery in
nine patients who had received APSAC compared with
Myocardial infarction is usually the result of thrombotic
occlusion of an atherosclerotic coronaty artery. The full
extent of myocardial damage, however, may not be estab-
lished for 26 hours, providing the rationale for early in-
tervention with thrombolytic agents to recanalize the oc-
cluded artery and reduce eventual infarct size (I).
Streptokinase is now widely used for this purpose, but be-
cause this drug induces a systemic fibrinolytic state its use
is associated with a significant risk of hemorrhagic com-
plications (2). Moreover, its short plasma half-life of only
18 minutes demands that it be administered by continuous
intravenous infusion (3).
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only one patient who had received placebo (56 versus
8%, p < 0.05). The 95% confidence limits for this 48%
difference between the groups are 20 to 76%. Arteri-
ography at 3 days showed persistent patency of all re-
canalized coronary arteries except one (APSAC group)
and also showed late recanalization in another four pa-
tients, three of whom had received APSAC. In the pa-
tients who had a patent infarct-related coronary artery
at the initial arteriographic study, patency was main-
tained throughout the study period regardless of whether
the patient was randomized to APSAC (n = 4) or pla-
cebo (n = 7). Complications related to APSAC therapy
were excessive bruising at the catheterization site in seven
patients and minor sensitivity reactions in three.
These data confirm the thrombolytic efficacy of AP-
SAC in acute myocardial infarction, and indicate that
the drug may be used safely by the intravenous route
with a 56% early recanalization rate.
(J Am Coli Cardiol1987;JO:20S-JO)
Anisoylated plasminogen streptokinase activator com-
plex (APSAC, previously called BRL 26921)has theoretical
advantages over streptokinase, although these are only par-
tially fulfilled in practice. The active serine site within the
streptokinase-plasminogen complex has been acylated with
p-anisoic acid. Acylation renders the complex catalytically
inert and prohibits its reaction with circulating plasminogen
and plasma inhibitors (4). Fibrin binding at the site of recent
thrombosis, however, is unaffected and after hydrolytic de-
acylation (T1J2 = 40 minutes) activation of the plasminogen
moiety to plasmin initiates the fibrinolytic cascade (5). De-
pending on the extent to which these novel properties of
APSAC are realized, two theoretical advantages will emerge.
First the consumption of circulating fibrinogen will be lim-
ited, reducing the risk of hemorrhagic complications. Sec-
ond, delay in plasma inhibition will prolong the plasma half-
life, allowing the drug to be administered as a single intra-
venous bolus injection.
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Despite the theoretical advantages of APSAC over strep-
tokinase, the thrombolytic efficacy of this new agent after
intravenous administration has not been subjected to the
same rigorous testing involving pre- and postdosing coro-
nary arteriography to document drug-induced recanalization
of the occluded infarct-related coronary artery (6-11). Our
study was designed to examine the thrombolytic efficacy of
intravenous APSAC in acute myocardial infarction using
strict arteriographic criteria and double-blind placebo con-
trol.
Methods
Study patients. Forty patients (35 men and 5 women)
aged :::::70 years (average 56 ± 9, range 27 to 70) were
included in this study of anisoylated plasminogen strepto-
kinase activator complex (APSAC) over a period of 18
months. Criteria for inclusion in the study were the recent
onset of cardiac chest pain (:::::6 hours before randomization
to APSAC or placebo) associated with ST segment elevation
>0.1 mV in a standard electrophysiologic (ECG) lead or
0.2 mV in a precordial lead. In all cases these ECG indexes
of acute infarction (anterior in 21, inferior in 19) were dem-
onstrated to persist despite treatment with sublingual or in-
travenous nitrates. Exclusion criteria included a history of
cerebrovascular accident, surgery or active peptic ulceration
within the previous 3 months. Patients with severe hyper-
tension (blood pressure > 200/120 mm Hg) or heart failure
and those who had had external cardiac massage were also
excluded. All patients gave informed verbal consent for
inclusion in the study, which had been approved by the
hospital ethical committee.
Protocol. Patients who fulfilled inclusion criteria for the
study underwent immediate coronary arteriography to iden-
tify the degree of patency of the infarct-related coronary
artery. Patients were then randomized to treatment with
APSAC, 30 mg intravenously, or with placebo. Coronary
arteriography was repeated 90 minutes later to determine
any change in the degree of patency of the infarct-related
coronary artery. Four hours after treatment with APSAC or
placebo, intravenous heparin, 1,000 units hourly, was started.
Heparin therapy continued until the final coronary arterio-
graphic study approximately 3 days later (range 25 to 139
hours), although in 18 patients the dose was either reduced
or subcutaneous heparin, 5,000 units every 8 hours, was
substituted. During the study period, drugs routinely used
for the management of myocardial infarction were not with-
held.
Coronary arteriography. The predosing coronary ar-
teriograms were performed in a side room attached to the
coronary care unit. The coronary arteries were imaged in
tum, starting with the (predicted) noninfarct-related vessel,
using a modified Judkins technique. After insertion of a
short sheath in the right femoral artery, the catheter was
positioned in the coronary ostium under fluoroscopic con-
trol. Arteriography was performed using 5 to 8 ml of Uro-
grafin-370 solution, and the images were recorded on vid-
eotape. Single views in the posteroanterior projection were
used in all cases, but when difficulties were encountered
identifying the branches of the left coronary artery, the left
lateral projection was also used. After the predosing coro-
nary arteriograms were obtained, the femoral sheath was
left in position and patency was maintained with a slow
infusion of normal saline solution. The 90 minute postdosing
coronary arteriograms were performed in exactly the same
manner, except that injection was made only into the infarct-
related coronary artery. The arterial sheath was not removed
until at least 24 hours afterward.
The sole purpose of the pre- and postdosing arterio-
graphic studies was to identify and determine the patency
of the infarct-related coronary artery. In every case, the
arteriograms recorded on videotape were adequate for this
purpose. The coronary arteriograms performed 3 days after
treatment, however, had the additional purpose of guiding
further management. For this reason, they were performed
in the cardiac catheterization laboratory using multiple ra-
diographic projections recorded on cine film.
Randomization. Patients were randomized to intrave-
nous treatment with APSAC, 30 mg in 5 ml of water (n =
20), or an identical preparation of placebo (n = 20). The
placebo consisted of freeze-dried human albumin in lysine-
mannitol, which was the base for the active preparation.
Randomization was double-blind. The drugs were injected
through a cannula in a peripheral vein over a period of 2
to 5 minutes. After drug administration, no further veni-
puncture was performed for 12 hours. During this period
all blood samples were obtained from the femoral arterial
sheath.
Analysis of arteriographic data. In one patient with a
persistently occluded coronary artery, equipment failure
prevented recording of the pre- and postdosing coronary
arteriograms on videotape. In four other patients, coronary
arteriography at 3 days was not performed because of clin-
ical deterioration or death in three and the request of the
referring physician in one. The remainder of the arterio-
graphic recordings were complete and were reported by a
cardiologist not included in the authorship of this paper who
was provided with no clinical details and was unaware of
the randomization sequence. Coronary patency was graded
according to the criteria of the TIMI study group (12). For
the purpose of our study, coronary recanalization required
positive demonstration of a change from TIMI grade 0 or
I at the predosing arteriogram to TIMI grade 2 or 3 at
subsequent arteriograms.
Statistical analysis. Chi-square testing was used to eval-
uate differences between the incidence of coronary reca-
nalization in the APSAC and placebo groups. All averaged
values were expressed as mean ± I SO.
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Figure 1. Effects of intravenous an-
isoylated plasminogen streptokinase
activator complex (APSAC) versus
placebo on coronary patency in the 29
patients with an occluded infarct-re-
lated coronary artery (lRCA),
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Results
The major results of the thrombolytic efficacy of ani-
soylated plasminogen streptokinase activator complex (AP-
SAC) in 29 patients with an occluded infarct-related coro-
nary artery are summarized in Figure I,
Predosing coronary arteriogram. The predosing coro-
nary arteriogram was performed 3, I ± 1,2 hours (range
0,75 to 5,75) after the onset of chest pain, In 29 patients
(group A), a TIMI grade 0 or I occlusion was identified in
the infarct-related coronary artery. The occluded vessels
were the left anterior descending coronary artery in 14 pa-
tients, the right coronary artery in 14 and the circumflex
coronary artery in I. In 11 patients (group B), the infarct-
related coronary artery already showed TIMI grade 22 pat-
ency involving the left anterior descending coronary artery
in 7 patients and the right coronary artery in 4, The time
from the onset of chest pain to the predosing coronary ar-
teriogram was similar in groups A (3, I ± 1,2 hours) and
B (3.0 ± 1.4 hours).
Randomization. Randomization to APSAC, 30 mg in-
travenously, or placebo was performed 3.3 ± I. 3 hours
(range 1.0 to 6.0) after the onset of chest pain. Of the 29
patients in group A, 16 received APSAC and 11 received
placebo. Of the 11 patients in group B, 4 received APSAC
and 7 received placebo.
Postdosing coronary arteriogram. Ninety minutes after
dosing, repeat coronary arteriography was performed. In
group A this demonstrated TIMI grade 22 recanalization
of the infarct-related coronary artery in 9 (56%) of the 16
patients who received APSAC compared with only I of the
13 patients who received placebo (p < 0.05). Recanalization
occurred in the right coronary artery in three patients, the
left anterior descending coronary artery in six and the cir-
cumflex coronary artery in one. These differences were not
significant. In group B, persistent patency of the infarct-
related coronary artery was demonstrated in all I I patients
90 minutes after dosing, regardless of treatment.
Diagnostic coronary arteriography. Approximately 3
days after randomization to APSAC or placebo, coronary
arteriography was repeated. In group A this showed per-
sistent patency of all but one recanalized infarct-related
coronary artery (a patient treated with APSAC whose right
coronary artery had reoccluded). Late recanalization of the
infarct-related coronary artery was demonstrated in four pa-
tients (three of whom had received APSAC), although clin-
ical benefit in terms of myocardial salvage is unlikely to
have been significant. Thus, at 3 days, recanalization was
established in 69% of patients treated with intravenous AP·
SAC compared with 15% of those who received placebo (p
< 0.05). In group B, coronary arteriography at 3 days
showed persistent patency of the infarct-related coronary
artery in all cases.
Procedural and drug-related complications. Compli-
cations of coronary arteriography included two episodes of
ventricular fibrillation that occurred during the predosing
procedure and responded rapidly to electrical cardioversion.
One patient developed severe but ultimately reversible isch-
emia of the leg, probably due to embolization from the
catheterization site. There were no side effects related to
the administration of placebo, but two patients developed
mild diaphoresis and dyspnea shortly after the APSAC in-
jection. In both cases this resolved spontaneously within a
period of 10 minutes. One other patient developed asymp-
tomatic hypotension (90/60 mm Hg) for 15 minutes after
the APSAC injection.
Bleeding complications were limited to bruising around
the femoral artery catheterization site, although in no case
was this severe enough to warrant blood transfusion. Never-
theless in eight patients, seven of whom received APSAC,
bruising was more pronounced than would normally be ex-
pected after cardiac catheterization and was attributed to the
effects of thrombolytic (ASPAC) and anticoagulant (hepa-
rin) therapy.
Clinical course. All patients except one (group B) de-
veloped completed myocardial infarction by cardiac enzy-
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matic criteria with peak plasma creatine kinase exceeding
twice the upper reference limit for our laboratory(200 IV/liter).
Three patients (two of whom received APSAC) died 3 to 5
days after admission because of intractable left ventricular
failure in each case. In none of these patients was death
attributable to APSAC therapy.
Discussion
Laffel and Braunwald (13) pointed out that many patients
who have undergone successful pharmacologically mediated
thrombolysis would have had early spontaneous thrombol-
ysis even if they had not received a thrombolytic agent. For
this reason, they emphasized the need for well designed
prospective randomized clinical trials to test the efficacy of
thrombolytic agents in acute myocardial infarction. The pur-
pose of our study was to define the thrombolytic efficacy
of intravenous anisoylated plasminogen streptokinase acti-
vator complex (APSAC) versus placebo in acute myocardial
infarction by arteriographic documentation of the coronary
anatomy before and after treatment. This information is
essential to define the potential of this new agent for re-
canalization of the infarct-related coronary artery after
thrombotic occlusion. No attempt was made to evaluate the
effects of treatment on the evolution of myocardial infarction
because the study was not primarily designed for this pur-
pose. The findings demonstrate that intravenous APSAC is
significantly more effective than placebo for thrombolysis
in acute myocardial infarction and leads to early recanali-
zation of the infarct-related coronary artery in 56% of cases.
Importantly, none of our patients developed severe hem-
orrhagic complications related to APSAC therapy.
Previous experience with APSAC. Previous studies
(14-18) in which APSAC was delivered by the intracoro-
nary route have consistently demonstrated recanalization of
the infarct-related coronary artery in>70% of cases. Similar
recanalization rates have been reported after intravenous
administration of the drug, particularly in studies (19-24)
in which "recanalization" was inferred from arteriographic
demonstration of coronary patency after treatment was given.
These studies, however, have almost certainly overesti-
mated the true drug-induced recanalization rate because in
a significant proportion of cases with recent myocardial
infarction, the infarct-related coronary artery is already pat-
ent at the time of hospital admission. Thus, our own pre-
dosing arteriographic findings demonstrated patency of the
infarct-related coronary artery in 11 (28%) of the 40 patients,
all of whom required exclusion from the analysis of the
thrombolytic efficacy of APSAC. Had these patients been
included and the thrombolytic efficacy of APSAC been as-
sessed on the postdosing arteriograms, we would have re-
ported a 70% recanalization rate rising to 80% at 3 days.
Certainly, therefore, the 100% APSAC-induced recanali-
zation rate reported by Doenecke et al. (22) and based on
postdosing arteriographic findings at 48 hours must be in-
terpreted cautiously.
Marder et al. (25) provided preliminary pre- and post-
dosing arteriographic data in patients with acute myocardial
infarction treated with 30 mg of intravenous APSAC. Their
finding of a 60% recanalization rate agrees with our own,
and is likely to provide a more realistic measure of the
thrombolytic efficacy of this new agent. Interestingly, this
is similar to the 57% recanalization rate after intravenous
streptokinase that Schroder (26) reported in his review of
pooled data from six studies in which pre- and postdosing
coronary arteriography were performed in acute myocardial
infarction. Indeed, there is probably no reason why the
thrombolytic efficacy of APSAC should be significantly dif-
ferent from that of streptokinase, because streptokinase is
the active component of the APSAC complex.
Spontaneous thrombolysis. Accurate assessment of the
efficacy of new thrombolytic agents in acute myocardial
infarction requires not only pre- and postdosing arteriog-
raphy, but also a placebo group to control for spontaneous
thrombolysis leading to recanalization of the infarct-related
coronary artery (27). Thus, spontaneous thrombolysis prob-
ably accounted for the high incidence of patency of the
infarct-related coronary artery at the predosing arteriogram
and for the recanalization that was demonstrated in the con-
trol group at the postdosing arteriogram (8%) and at the
diagnostic arteriogram after 3 days (15%). Been et al. (21)
included a placebo group in their randomized study of 32
patients given intravenous APSAC, 30 mg, early after the
onset of myocardial infarction. Although they did not obtain
predosing arteriograms, their findings, like our own, clearly
demonstrate that early patency of the infarct-related coro-
nary artery occurs significantly more often in patients treated
with APSAC than in patients treated with placebo. Other
randomized studies (28,29) using noninvasive functional
markers of recanalization lend support to this conclusion.
Thrombolytic therapy in patients with a patent in-
farct-related coronary artery. Patency of the infarct-re-
lated coronary artery is a commonly observed phenomenon
in angiographic studies of acute myocardial infarction (30),
and was demonstrated in 28% of our patients at the pre-
dosing investigation. It has been suggested (31,32) that the
natural history of coronary occlusion in atherosclerotic ar-
teries involves a dynamic interaction of thrombosis, endog-
enous thrombolysis and alterations in arterial tone. Because
thrombolytic agents have the potential to influence this dy-
namic process favorably, treatment of this type might the-
oretically be helpful even in patients with patent infarct-
related coronary arteries. Nevertheless, our own findings
suggest that in patients who present with a patent infarct-
related coronary artery, patency is maintained regardless of
thrombolytic therapy. This conclusion must be interpreted
cautiously, however, because our numbers were small and
all of our patients received vasodilators and heparin, which
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are likely to have had an independent influence on coronary
patency separate from the effects of thrombolytic therapy.
Advantages of APSAC versus streptokinase. Our study
indicates that the thrombolytic efficacy of intravenous AP-
SAC is similar to that of streptokinase. APSAC has the
theoretical advantage, however, of producing less systemic
fibrinolysis (4). Nevertheless, although hemorrhagic com-
plications in our study were relatively trivial, other inves-
tigators have reported more serious complications including
gastrointestinal and intracranial bleeding with dosage reg-
imens similar to our own (23,24). Indeed, measurements
of circulating fibrinogen after intravenous APSAC, 30 mg,
have shown profound hypofibrinogenemia (19,23,24), which
in one study was comparable with that observed after admin-
istration of 1.5 million units of streptokinase or 2 million
units of urokinase. It is clear, therefore, that whereas low
doses of APSAC (5 to 20 mg) may have a relatively atten-
uated effect on systemic coagulation variables (17), the ef-
fect is considerably more pronounced with higher doses.
This undoubtedly exposes the patient to the risk of hem-
orrhagic complications, but at the same time may contribute
to successful and permanent reperfusion (33).
The minor sensitivity reactions that occurred in three
patients after APSAC were similar to those that occasionally
complicate streptokinase therapy and were presumably due
to the antigenicity of the complex (34). In this respect,
therefore, APSAC appears to offer no advantage over strep-
tokinase. Larger studies are necessary to determine the prev-
alance and potential severity of APSAC-induced hypersen-
sitivity before recommendations for prophylactic corticosteroid
therapy can be made.
Other potential advantages ofAPSAC over streptokinase
relate to its sustained thrombolytic action, which continues
for up to 8 hours after administration and may reduce the
incidence of reocclusion after initial recanalization (35).
Nevertheless, as Hillis and Hornung (36) commented in a
recent review, . 'The major advantage of APSAC is its rate
of administration as a single bolus injection over five min-
utes which may allow its application to use in the community
by the primary care doctor, the hospital emergency depart-
ment or the coronary care setting." The benefits of APSAC
in the coronary care setting have now been substantiated by
Ikram et al. (29) in a randomized study of 149 patients.
They found that in patients randomized to APSAC within
150 minutes of the onset of symptoms, confirmed infarction
(by enzymatic criteria) developed less commonly than in
those treated conventionally (84 versus 100%, p < 0.05).
This indicates that APSAC may play an important role in
the coronary care unit for the early management of myo-
cardial infarction. Our own data suggest that up to 56% of
patients may benefit from treatment of this type.
Limitation of study. The principal limitation of our
study is the small number of patients randomized. Thus,
although the best estimate of the difference between treat-
ment groups for patients showing early coronary recanali-
zation is 48%, the 95% confidence limits range from 20 to
76%. Importantly, however, even at the lowest limit of
confidence there is an appreciable advantage of APSAC over
placebo. The small number of patients studied also places
constraints on the analysis of complications. A more mean-
ingful assessment of the clinical safety of APSAC would
require studies on a much larger scale. An additional lim-
itation of the present study relates to the image quality of
the videotape recordings of the acute phase coronary arte-
riograms, which was inevitably inferior to that of the cine
recordings obtained at 3 days in the catheterization labo-
ratory. In no case, however, did the image quality preclude
identification of the infarct-related coronary artery. More-
over, because our criteria for recanalization discounted sub-
tle (TIMI grade I) penetration of the occlusion and required
instead full opacification of the distal vessel (TIMI grade 2
or 3), it is unlikely that our assessment of the thrombolytic
efficacy of APSAC represented a significant underestimate.
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